The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Current Eligibility Requirements for CGM Coverage Are Harmful, Costly, and Unjustified
Open accessAbstract
An alarming proportion of individuals with diabetes are not achieving their individualized goals. Several recent randomized controlled trials and real-world observational studies have demonstrated that use of continuous glucose monitoring (CGM) improves clinical and psychosocial outcomes individuals with type 1 and type 2 diabetes. However, CGM use is denied to many individuals who could benefit from this technology due to eligibility criteria that require a documented history of frequent self-monitoring of blood glucose (SMBG). In this article, we discuss the absence of evidence supporting coverage policies and present data demonstrating that prior frequency of SMBG is not predictive of successful CGM use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Economic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 2×
“One approach would be to compare the percentage of study subjects who achieved significant clinical benefit, as was done in the recent analyses.(7,12,14,31) This approach provides both an opportunity to identify and elucidate the characteristics of those patients who are most (or least) suited for the CGM use and the…”
MethodResultSelf-citationBolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
Beck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2855 · Cited by 635
Self-citationHaak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · cited 5×
“Numerous large randomized trials have demonstrated the efficacy of CGM use in individuals with T1D and insulintreated T2D.(13,14) Specific benefits include reductions in A1c and glycemic variability; increased time in target glycemic range; decreased time in hypoglycemic range; and fewer hypoglycemic events.”
BackgroundMethodInfluentialHeinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522
Yeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes
Monnier, L., Colette, C., Wojtusciszyn, A., Dejager, S., Renard, E., Molinari, N., & Owens, D. R. (2017) · Diabetes Care · doi:10.2337/dc16-1769 · Cited by 390 · cited 1×
“Investigators also found that rtCGM use resulted in a significant decrease in the frequency of clinical severe hypoglycemia and reduced glycemic variability, a known risk factor for hypoglycemia.(32,33) Moreover, the most recent data from the T1D Exchange registry showed clear associations between UNJUSTIFIED CGM ELIG…”
Backgroundvan Beers, C. A. J., DeVries, J. H., Kleijer, S. J., Smits, M. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Diamant, M., Snoek, F. J., & Serné, E. H. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30193-0 · Cited by 386 · cited 1×
“Importantly, CGM use has been shown to be particularly effective among those with frequent severe hypoglycemia and/or hypoglycemia unawareness.(10,11) Recognizing the importance of glucose monitoring, especially for insulin-treated patients, the ADA recommends that most patients using intensive insulin regimens (multi…”
BackgroundReal-time continuous glucose monitoring among participants in the T1D Exchange clinic registry
Wong, J. C., Foster, N. C., Maahs, D. M., Raghinaru, D., Bergenstal, R. M., Ahmann, A. J., Peters, A. L., Bode, B. W., Aleppo, G., Hirsch, I. B., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0303 · Cited by 318
Tanenbaum, M. L., Hanes, S. J., Miller, K. M., Naranjo, D., Bensen, R., & Hood, K. K. (2017) · Diabetes Care · doi:10.2337/dc16-1536 · Cited by 296 · cited 1×
“A similar survey identified ‘‘cost of supplies’’ as the top reason for discontinuing CGM use.(5) Therefore, even when CGM is covered, the out-of-pocket expense may be too high for many patients.”
BackgroundŠoupal, J., Petruželková, L., Grunberger, G., Hásková, A., Flekač, M., Matoulek, M., Mikeš, O., Pelcl, T., Škrha, J., Horová, E., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0888 · Cited by 242
Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014
Carls, G., Huynh, J., Tuttle, E., Yee, J., & Edelman, S. V. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0280-5 · Cited by 228 · cited 1×
“Despite ongoing advances in medications, insulin delivery systems, and glucose monitoring technologies, diabetes control remains suboptimal in many individuals with this disease.(1) In addition to the clinical consequences resulting from poor control is the ever-increasing financial burden on individuals, health syste…”
BackgroundPoolsup, N., Suksomboon, N., & Kyaw, A. M. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-39 · Cited by 179
Yeoh, E., Choudhary, P., Nwokolo, M., Ayis, S., & Amiel, S. A. (2015) · Diabetes Care · doi:10.2337/dc15-0102 · Cited by 154
Šoupal, J., Petruželková, L., Flekač, M., Pelcl, T., Matoulek, M., Daňková, M., Škrha, J., Svačina, Š., & Prázný, M. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0171 · Cited by 126
Beck, R. W., Riddlesworth, T. D., Ruedy, K. J., Kollman, C., Ahmann, A. J., Bergenstal, R. M., Bhargava, A., Bode, B. W., Haller, S., Kruger, D. F., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30217-6 · Cited by 119
Self-citationChetty, V. T., Almulla, A., Odueyungbo, A., & Thabane, L. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.02.014 · Cited by 85
Cited by
Addala, A., Maahs, D. M., Scheinker, D., Chertow, S., Leverenz, B., & Prahalad, P. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13082 · Cited by 83
“For example, in order to receive and maintain approval for CGM coverage for children in California, public insurance policies have long required at least three fingerstick blood glucose checks per day, despite limited clinical need once on a CGM.10 Data from national and international registries demonstrate that the u…”
BackgroundInfluentialGrace, T., & Salyer, J. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0212 · Cited by 64
“Thus, the majority of T2D patients are denied access to this technology unless they are willing to pay out-of-pocket.(16) We report findings from a single-arm study of rtCGM use within cohort of adult T2D patients treated with basal insulin only or noninsulin therapies.”
BackgroundFantasia, K. L., Wirunsawanya, K., Lee, C., & Rizo, I. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821995810 · Cited by 62
Tanenbaum, M. L., Zaharieva, D. P., Addala, A., Ngo, J., Prahalad, P., Leverenz, B., New, C., Maahs, D. M., & Hood, K. K. (2021) · Diabetic Medicine · doi:10.1111/dme.14567 · Cited by 42
Chesser, H., Srinivasan, S., Puckett, C., Gitelman, S. E., & Wong, J. C. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221139873 · Cited by 40
Metadata
- Authors
- Anderson, J. E., Gavin, J. R., & Kruger, D. F.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2020-03-01
- Volume
- 22
- Issue
- 3
- Pages
- 169-173
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2979588042
- Cited by
- 77
- References
- 19
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.